1Division of Gastroenterology and Hepatology, Virginia Commonwealth University, Richmond, Virginia. Electronic address: Mohammad.email@example.com.
2Department of Pathology, Virginia Commonwealth University, Richmond, Virginia.
3Zydus Discovery DMCC, Dubai, United Arab Emirates.
4Southern Therapy and Advanced Research LLC, Jackson, Mississippi.
5Clinical Trials of Texas, Inc, San Antonio, Texas.
6American Research Corporation, The Texas Liver Institute, San Antonio, Texas.
7Digestive Health Research/Objective GI, Nashville, Tennessee.
8Gastro One, Clinical Research Department, Germantown, Tennessee.
9Division of Gastroenterology and Hepatology, Virginia Commonwealth University
Nonalcoholic steatohepatitis (NASH), the clinically aggressive variant of nonalcoholic fatty liver disease, is characterized by hepatocellular injury and inflammation.1 Patients with NASH are at higher risk of progression to cirrhosis and it is therefore targeted for drug development efforts.2Lifestyle modifications and weight loss are the only recommended modalities and no drug is yet approved for the treatment of patients with NASH. Saroglitazar is a dual PPAR α/γ agonist, which has shown promise for treatment of nonalcoholic fatty liver disease.3 Because of its combined PPAR-α/γ agonism, it has a clinically favorable impact of glucose and lipid metabolism. Saroglitazar has shown to improve liver-related histology in patients with NASH and was recently approved for treatment of NASH in India.4 The current study builds on the published literature in this proof of concept study to determine if there is a signal for histologic improvement of NASH with saroglitazar in a Western population.